Objective To research the clinical evaluation of potassium dehydroandrograpolide succinate injection in the treatment of COPD combined with CAP and its influence on plasma IL-33, PCT and hs-CRP levels.Method 91 patients with COPD combined with CAP in our hospital from April 2015 to August 2016 were selected and divided into the observation group (48 cases) and the control group (43 cases).The control group was given routine treatment, the observation group was given on the basis of the above treatment of potassium dehydroandrograpolide succinate injection.The clinical efficacy and plasma IL-33, PCT and hs-CRP levels were compared between the two groups after treatment.Results Before treatment, the IL-33, PCT, hs-CRP of two groups of patients had no significant difference.After treatment, the total effective rate of the observation group was 91.67% higher than that of the control group 74.42%, the difference was statistically significant (P<0.05).All the clinical symptoms time of the observation group was significantly lower than that of the control group, and the clearance rate of the observation group (85.42%) was significantly higher than that of the control group (67.44%), the difference was statistically significant (P<0.05), the indexes of the two groups of patients were decreased, the indexes of the observation group significantly lower than that in control group, the difference was statistically significant (P<0.05).There was no significant difference in the incidence of adverse reactions between the observation group and the control group .Conclusion Potassium dehydroandrograpolide succinate injection can significantly improve their plasma IL-33, PCT and hs-CRP levels, the respiratory pathogen and inflammatory mediators are effectively removed, and has good clinical effect, and no serious adverse reactions during treatment.